An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.
Where this comes from
- Record sourced from PubMed, PMID 34598944.
- Also identified by DOI 10.1158/1078-0432.CCR-21-3029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.<i>See related article by Terry et al., p. 6749</i>.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms